Skip to main content
Erschienen in: Surgery Today 8/2017

01.03.2017 | Original Article

A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy

verfasst von: Kazuhiro Migita, Sohei Matsumoto, Kohei Wakatsuki, Masahiro Ito, Tomohiro Kunishige, Hiroshi Nakade, Mutsuko Kitano, Mitsuhiro Nakatani, Hiromichi Kanehiro

Erschienen in: Surgery Today | Ausgabe 8/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The aim of this study was to evaluate the prognostic impact of the prognostic nutritional index (PNI) in gastric cancer patients undergoing neoadjuvant chemotherapy (NAC).

Methods

This study reviewed 54 patients with gastric cancer who underwent NAC and a subsequent R0 gastrectomy. The PNI before starting NAC and before gastrectomy were calculated using the following formula: 10 × serum albumin (g/dl) + 0.005 × total lymphocyte count (per mm3). A multivariate analysis was performed to identify the predictors of overall survival (OS).

Results

The mean pre-NAC and preoperative PNI were 48.3 ± 5.1 and 48.2 ± 4.7, respectively (p = 0.934). The PNI decreased after NAC in 31 patients (57.4%). The pre-NAC PNI and preoperative PNI were not significantly associated with the OS rate. The 3-year OS rate in patients with the decreased PNI values was significantly lower than that in the patients whose PNI values were either maintained or increased (41 vs. 76.4%, p = 0.003). A multivariate analysis revealed that a decreased PNI value was an independent predictor of a poor OS (p = 0.006).

Conclusions

Decreased PNI values were associated with worse long-term outcomes in gastric cancer patients undergoing NAC.
Literatur
1.
Zurück zum Zitat Bedikian AY, Chen TT, Khankhanian N, Heilbrun LK, McBride CM, McMurtrey MJ, et al. The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol. 1984;2:305–10.CrossRefPubMed Bedikian AY, Chen TT, Khankhanian N, Heilbrun LK, McBride CM, McMurtrey MJ, et al. The natural history of gastric cancer and prognostic factors influencing survival. J Clin Oncol. 1984;2:305–10.CrossRefPubMed
2.
Zurück zum Zitat Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRefPubMed Andreyev HJ, Norman AR, Oates J, Cunningham D. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;34:503–9.CrossRefPubMed
3.
Zurück zum Zitat Mariette C, De Botton ML, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol. 2012;19:2128–34.CrossRefPubMed Mariette C, De Botton ML, Piessen G. Surgery in esophageal and gastric cancer patients: what is the role for nutrition support in your daily practice? Ann Surg Oncol. 2012;19:2128–34.CrossRefPubMed
4.
Zurück zum Zitat Migita K, Takayama T, Saeki K, Matsumoto S, Wakatsuki K, Enomoto K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol. 2013;20:2647–54.CrossRefPubMed Migita K, Takayama T, Saeki K, Matsumoto S, Wakatsuki K, Enomoto K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol. 2013;20:2647–54.CrossRefPubMed
5.
Zurück zum Zitat Qiu M, Zhou YX, Jin Y, Wang ZX, Wei XL, Han HY, et al. Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Support Care Cancer. 2015;23:1933–9.CrossRefPubMed Qiu M, Zhou YX, Jin Y, Wang ZX, Wei XL, Han HY, et al. Nutrition support can bring survival benefit to high nutrition risk gastric cancer patients who received chemotherapy. Support Care Cancer. 2015;23:1933–9.CrossRefPubMed
6.
Zurück zum Zitat Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8:339–45.CrossRefPubMedPubMedCentral Liu X, Sun X, Liu J, Kong P, Chen S, Zhan Y, et al. Preoperative C-reactive protein/albumin ratio predicts prognosis of patients after curative resection for gastric cancer. Transl Oncol. 2015;8:339–45.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001–5.PubMed Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85:1001–5.PubMed
8.
Zurück zum Zitat Sun KY, Xu JB, Chen SL, Yuan YJ, Wu H, Peng JJ, et al. Novel immunological and nutritional-based prognostic index for gastric cancer. World J Gastroenterol. 2015;21:5961–71.PubMedPubMedCentral Sun KY, Xu JB, Chen SL, Yuan YJ, Wu H, Peng JJ, et al. Novel immunological and nutritional-based prognostic index for gastric cancer. World J Gastroenterol. 2015;21:5961–71.PubMedPubMedCentral
9.
Zurück zum Zitat Sakurai K, Ohira M, Tamura T, Toyokawa T, Amano R, Kubo N, et al. Predictive potential of preoperative nutritional status in long-term outcome projections for patients with gastric cancer. Ann Surg Oncol. 2016;23:525–33.CrossRefPubMed Sakurai K, Ohira M, Tamura T, Toyokawa T, Amano R, Kubo N, et al. Predictive potential of preoperative nutritional status in long-term outcome projections for patients with gastric cancer. Ann Surg Oncol. 2016;23:525–33.CrossRefPubMed
10.
Zurück zum Zitat Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.CrossRefPubMed
11.
Zurück zum Zitat Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:4387–93.CrossRefPubMed
12.
Zurück zum Zitat Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9.CrossRefPubMed Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1–9.CrossRefPubMed
13.
Zurück zum Zitat Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015–22.CrossRefPubMed Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015–22.CrossRefPubMed
14.
Zurück zum Zitat Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRefPubMed Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101:653–60.CrossRefPubMed
15.
Zurück zum Zitat Migita K, Nashimoto A, Yabusaki H, Matsuki A, Aizawa M. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. Int J Clin Oncol. 2016;21:102–9.CrossRefPubMed Migita K, Nashimoto A, Yabusaki H, Matsuki A, Aizawa M. Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. Int J Clin Oncol. 2016;21:102–9.CrossRefPubMed
16.
Zurück zum Zitat Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer. 2012;118:4785–94.CrossRefPubMed Hiura Y, Takiguchi S, Yamamoto K, Takahashi T, Kurokawa Y, Yamasaki M, et al. Effects of ghrelin administration during chemotherapy with advanced esophageal cancer patients: a prospective, randomized, placebo-controlled phase 2 study. Cancer. 2012;118:4785–94.CrossRefPubMed
17.
Zurück zum Zitat Yoshida N, Watanabe M, Baba Y, Ishimoto T, Iwagami S, Sakamoto Y, et al. Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer. Dis Esophagus. 2014;27:374–9.CrossRefPubMed Yoshida N, Watanabe M, Baba Y, Ishimoto T, Iwagami S, Sakamoto Y, et al. Influence of preoperative docetaxel, cisplatin, and 5-fluorouracil on the incidence of complications after esophagectomy for resectable advanced esophageal cancer. Dis Esophagus. 2014;27:374–9.CrossRefPubMed
18.
Zurück zum Zitat Steyn RS, Grenier I, Darnton SJ, Cullen MH, Matthews HR. Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. Clin Oncol (R Coll Radiol). 1995;7:382–4.CrossRef Steyn RS, Grenier I, Darnton SJ, Cullen MH, Matthews HR. Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. Clin Oncol (R Coll Radiol). 1995;7:382–4.CrossRef
19.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastr Cancer. 2011;14:101–12.CrossRef Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastr Cancer. 2011;14:101–12.CrossRef
20.
Zurück zum Zitat Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastr Cancer. 2011;14:113–23.CrossRef Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastr Cancer. 2011;14:113–23.CrossRef
21.
Zurück zum Zitat Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205–13.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, et al. Postoperative prognostic nutritional index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Am J Surg. 2016;212:122–7.CrossRefPubMed Peng W, Li C, Wen TF, Yan LN, Li B, Wang WT, et al. Postoperative prognostic nutritional index change is an independent predictor of survival in patients with small hepatocellular carcinoma. Am J Surg. 2016;212:122–7.CrossRefPubMed
23.
Zurück zum Zitat Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Support Care Cancer. 2005;13:270–4.CrossRefPubMed Bauer JD, Capra S. Nutrition intervention improves outcomes in patients with cancer cachexia receiving chemotherapy—a pilot study. Support Care Cancer. 2005;13:270–4.CrossRefPubMed
24.
Zurück zum Zitat Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011;117:1775–82.CrossRefPubMed Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer. 2011;117:1775–82.CrossRefPubMed
25.
Zurück zum Zitat Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011;117:3774–80.CrossRefPubMed Murphy RA, Mourtzakis M, Chu QS, Baracos VE, Reiman T, Mazurak VC. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011;117:3774–80.CrossRefPubMed
26.
Zurück zum Zitat Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer. 2004;91:447–52.CrossRefPubMedPubMedCentral Isenring EA, Capra S, Bauer JD. Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. Br J Cancer. 2004;91:447–52.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr. 2012;96:1346–53.CrossRefPubMed Ravasco P, Monteiro-Grillo I, Camilo M. Individualized nutrition intervention is of major benefit to colorectal cancer patients: long-term follow-up of a randomized controlled trial of nutritional therapy. Am J Clin Nutr. 2012;96:1346–53.CrossRefPubMed
28.
Zurück zum Zitat Takiguchi S, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, et al. Impact of synthetic ghrelin administration for patients with severe body weight reduction more than 1 year after gastrectomy: a phase II clinical trial. Surg Today. 2016;46:379–85.CrossRefPubMed Takiguchi S, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, et al. Impact of synthetic ghrelin administration for patients with severe body weight reduction more than 1 year after gastrectomy: a phase II clinical trial. Surg Today. 2016;46:379–85.CrossRefPubMed
Metadaten
Titel
A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy
verfasst von
Kazuhiro Migita
Sohei Matsumoto
Kohei Wakatsuki
Masahiro Ito
Tomohiro Kunishige
Hiroshi Nakade
Mutsuko Kitano
Mitsuhiro Nakatani
Hiromichi Kanehiro
Publikationsdatum
01.03.2017
Verlag
Springer Japan
Erschienen in
Surgery Today / Ausgabe 8/2017
Print ISSN: 0941-1291
Elektronische ISSN: 1436-2813
DOI
https://doi.org/10.1007/s00595-017-1469-y

Weitere Artikel der Ausgabe 8/2017

Surgery Today 8/2017 Zur Ausgabe

Leitlinien kompakt für die Allgemeinmedizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Facharzt-Training Allgemeinmedizin

Die ideale Vorbereitung zur anstehenden Prüfung mit den ersten 24 von 100 klinischen Fallbeispielen verschiedener Themenfelder

Mehr erfahren

Update Allgemeinmedizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.